 random trial inoper non-small-cel lung cancer vindesin cisplatin versu mitomycin vindesin cisplatin versu etoposid cisplatin vindesin mitomycin patient inoper non-small-cel lung cancer nsclc dosag regimen vindesin cisplatin VP mitomycin vindesin cisplatin mvp etoposid cisplatin vindesin mitomycin ep/vm assess patient respons rate VP mvp ep/vm addit mitomycin VP regimen respons rate respons rate ep/vm regimen mvp regimen median surviv time VP week mvp week ep/vm week differ signific iii IV thrombocytopenia mvp patient VP other toxic similar group analys prognost factor treatment mvp sex histolog classif squamou cell carcinoma predict improv respons import factor improv surviv cox regress analysi stage diseas perform statu sex weight loss diagnosi hemoglobin concentr